If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
The ISOLDE facility contains the Class A laboratories, buildings for the HIE-ISOLDE and MEDICIS projects, and the control rooms located in building 508. Before ISOLDE, the radioactive nuclides were transported from the production are to the laboratory for examination. At ISOLDE, all processes from the production to the measurements are connected and the radioactive material requires no extra transport. Due to this, ISOLDE is referred to as an on-line facility. At the ISOLDE facility, the main proton beam for reactions comes from the PSB. The incoming proton beam has an energy of 1.4 GeV and its average intensity varies up to 2 μA. The beam enters the facility and is directed towards one of two mass separators: the General Purpose Separator (GPS) and the High Resolution Separator (HRS). The separators have independently run target-ion source systems, delivering 60 keV RIBs.
When signs of tolerance to midazolam occur during intensive care unit sedation the addition of an opioid or propofol is recommended. Withdrawal symptoms can include irritability, abnormal reflexes, tremors, clonus, hypertonicity, delirium and seizures, nausea, vomiting, diarrhea, tachycardia, hypertension, and tachypnea.
== Career == She began working as a biochemistry and nutrition professor at the University of San Martín de Porres in 2001. Many of her research projects have been financed by CONCYTEC. She was a member of the Advisory Committee of the School of Food Science from 2011 to 2013, and served as an undergraduate and postgraduate professor at UNMSM. Additionally, she taught at University of San Martín de Porres from 1998 to 2013 and at Cayetano Heredia University School of Pharmacy and Biochemistry from 2014 to 2015. From 2012 to 2016, Muñoz's investigative research and projects, were subsidized by her alma mater, UNMSM. As part of her academic growth, she has participated in congresses by a variety of institutions, including the Latin American Society of Nutrition, Chemical Society of Peru and Peruvian Society of Nutrition, of which she is a member. She was previously the President of the Chemical Society of Peru Magazine and has served as President of the Consultative Committee Hipolito Unanue Foundation since 2023. She was the Rector of San Ignacio de Loyola University (USIL) from 2022 to 2023. Previously, she was the Dean of Health Sciences at USIL from 2016 to 2017. Since 2023 she has been the Vice Rector of Research at USIL. She published her first book, Estudio químico-bromatológico del fruto Carica monoica desf., through Editorial Académica Española in 2012. She was a co-author of the 2020 book Nutrición e Inmunidad: salud en los tiempos de COVID-19.
Coloured representation was ended in 1968, leaving both the Senate and the House of Assembly representing white voters only. South West Africa ceased to be represented in Parliament from 1977, following the passing of the South West Africa Constitution Amendment Act of that year. The Senate was abolished with effect from 1 January 1981, changing Parliament to a unicameral legislature.
Sources: en.wikipedia.org
== Side effects == Among antibiotic drugs, meropenem is relatively safe. The most common adverse effects are diarrhea (4.8%), nausea and vomiting (3.6%), injection-site inflammation (2.4%), headache (2.3%), rash (1.9%) and thrombophlebitis (0.9%). Many of these adverse effects were observed in severely ill individuals already taking many medications including vancomycin. Meropenem has a reduced potential for seizures in comparison with imipenem. Several cases of severe hypokalemia have been reported.
=== Administrative work === In 1959, after offering advice to Yale president A. Whitney Griswold on strengthening the sciences at Yale, Fruton became director of the division of science, a position he held until 1962. His work led to the creation of the short-lived department of molecular biology and biophysics (MBB), although his initial proposal to create a similar department that combined the existing biophysics and biochemistry departments was rejected. Fruton became burnt out on Yale politics after an extended conflict with provost Kingman Brewster, in which Brewster attempted to bypass Fruton's science advisory committee and create a molecular biology department independent of biochemistry department; the MBB department was created only after Brewster had failed to attract a prominent scientist from outside Yale to head a molecular biology department, and the department of biochemistry remained separate as part of the medical school until the creation of the department of molecular biophysics & biochemistry (MB&B) in 1969 (which was itself created after a lengthy and unsuccessful attempt to find a suitably eminent replacement for Fruton to head the department of biochemistry). Fruton was elected to the American Philosophical Society in 1968.
Occasionally a radiologic diagnosis of disc degeneration is made incidentally when a cervical X-ray, chest X-ray, or abdominal X-ray is taken for other reasons and the abnormalities of the vertebral column are recognized. The diagnosis of DDD is not a radiologic diagnosis, since the interpreting radiologist is not aware whether there are symptoms. Typical radiographic findings include disc space narrowing, displacement of vertebral bodies, fusion of adjacent vertebral bodies, and development of bone in adjacent soft tissue (osteophyte formation). An MRI is typically reserved for those with symptoms, signs, and X-ray findings suggesting a need for surgical intervention. Treatment may include physical therapy for pain relief, ROM (range of motion), and appropriate muscle/strength training, with emphasis on correcting abnormal posture, assisting the paravertebral (paraspinous) muscles in stabilizing the spine, and core muscle strengthening; stretching exercises; massage therapy; oral analgesia with non-steroidal anti-inflammatory agents (NSAIDS); and topical analgesia with lidocaine, ice, and heat. Immediate surgery may be indicated if the symptoms are severe or sudden in onset, or suddenly worsen. Elective surgery may be indicated after six months of conservative therapy with unsatisfactory relief of symptoms.
=== Primary dentin === Primary dentin, the most prominent dentin in the tooth, lies between the enamel and the pulp chamber (near dentinoenamel junction). The outer layer closest to enamel is known as mantle dentin. This layer is unique to the rest of primary dentin. Mantle dentin is formed by newly differentiated odontoblasts and forms a layer consistently 15-20 micrometers (μm) wide. Unlike primary dentin, mantle dentin lacks phosphorylation, has loosely packed collagen fibrils and is less mineralized. Below it lies the circumpulpal dentin, more mineralized dentin which makes up most of the dentin layer and is secreted after the mantle dentin by the odontoblasts. Circumpulpal dentin is formed before the root formation is completed. Newly secreted dentin is unmineralized and is called predentin. It is easily identified in hematoxylin and eosin stained sections since it stains less intensely than dentin. It is usually 10-47μm and lines the innermost region of the dentin. It is unmineralized and consists of collagen, glycoproteins, and proteoglycans. It is similar to osteoid in bone and is thickest when dentinogenesis is occurring.
== Model systems == Human models for cystinosin are typically derived from cystinotic renal tubular cell lines. Non-human protein homologs for cystinosin include ERS1 in Saccharomyces cerevisiae (yeast cells) and the Caenorhabditis elegans protein, C41C4.7. Murine ctns has also been used.
Sources: en.wikipedia.org
Dexlansoprazole was launched as a follow up of lansoprazole in 2009. Dexlansoprazole is an (R)-(+)-enantiomer of lansoprazole, marketed as Dexilant. After oral appliance of the racemic lansoprazole, the circulating drug is 80% dexlansoprazole. Moreover, both enantiomers have similar effects on the proton pump. Consequently, the main advantage of Dexilant is not the fact that it is an enantiopure substance. The advantage is the pharmaceutical formulation of the drug, which is based on a dual release technology, with the first quick release producing a blood plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later.
== Non-functional proton coupled amino acid transporter == In hereditary disease iminoglycinuria, there is a defect in the human proton-coupled amino acid transporter 1 and 2 genes which results in a defect in the absorption of proline and glycine. Iminoglycinuria is an autosomal recessive disorder of the renal tubular. Lack of glycine and proline absorption leads to excess urinary excretions containing amino acids. If the transporters are not working properly, a drug that they usually help gain entry in to the cell might not be absorbed Their function can also be inhibited by tryptophan derivatives and allow for exploration into the function of hPAT1 and hPAT2. Additionally, mutations that lead to structural changes in amino acid binding sites play a role in their functional transport.
In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time (this can be done using liquid chromatography–mass spectrometry). In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called "area under the curve" or AUC) gives insight into the extent of exposure to a drug and its clearance rate from the body.
=== Canada === Vesta Creek (Alberta), a stream in northern Alberta Vesta Creek (Ontario), a stream in Bruce County, Ontario Vesta, a dispersed rural community in the municipality of Brockton, Bruce County, Ontario
Shānghán Zábìng Lùn (傷寒雜病論), or The Treatise on Cold Damage and Miscellaneous Diseases, is the first Chinese monograph on diseases by Zhang Zhongjing. The original work is lost, but most of its contents are preserved in two extant works called Shānghán Lùn (傷寒論; "The Treatise on Cold Damage") and Jīnguì Yàolüè (金匱要略; "Essential Prescriptions from the Golden Chamber"). The first work primarily addresses externally triggered conditions while the latter work describes internally generated conditions. Zhang's specialized chapter on xiāo kě is found in Shānghán Lùn and Jīnguì Yàolüè. Nine subsections and nine formulae (herbal remedies) on wasting-thirst were recorded. The text proposed a theory of "three wasting-thirsts": upper- (associated with the lungs), middle- (associated with the stomach), and lower- (associated with the kidneys), all three of which shared excessive urine and thirst as symptoms. This theory was later expanded through the works of Liu Wansu (1120–1200 AD) and Wang Kentang (1549–1613 AD). According to Liu, "lower wasting-thirst" attributed to "kidney-yin deficiency" was associated with sweet urine (glycosuria). This may indicate differentiation akin to modern-day differentiation of diabetes mellitus and diabetes insipidus.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.